

PHARMACY POLICY STATEMENT

North Carolina Marketplace

DRUG NAME	Litfulo (ritlecitinib)
BENEFIT TYPE STATUS	Pharmacy

CareSource considers Litfulo (ritlecitinib) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off -Label policy.

DATE	ACTION/DESCRIPTION
07/31/2023	New policy for Litfulo created.
09/27/2023	Added trial of topical therapy or an oral corticosteroid.

References:

1. Litfulo [package insert]. New York, NY; Pfizer Labs. 2023.
2. Messenger AG, McKillop J, Farrant P, McDonagh AJ, Sladden M. British Association of Dermatologists' guidelines for the management of alopecia areata 2012. *Br J Dermatol.* 2012;166(5):916-926. doi:10.1111/j.1365-2133.2012.10955.x
3. King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial [published correction appears in *Lancet.* 2023 Jun 10;401(10392):1928]. *Lancet.* 2023;401(10387):1518-1529. doi:10.1016/S0140-6736(23)00222-2
4. Harries MJ, Sun J, Paus R, King LE Jr. Management of alopecia areata. *BMJ.* 2010;341:c3671. Published 2010 Jul 23. doi:10.1136/bmj.c3671
5. Cranwell WC, Lai VW, Photiou L, et al. Treatment of alopecia areata: An Australian expert consensus statement. *Australas J Dermatol.* 2019;60(2):163-170. doi:10.1111/ajd.12941
6. Almutairi N, Nour TM, Hussain NH. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study. *Dermatology.* 2019;235(2):130-136. doi:10.1159/000494613

Effective date: 01/01/2024
 Creation date: 09/27/2023